Frank Baldino, Jr.. Ph.D. is the founder, chairman and CEO of international biopharmaceutical company, Cephalon, Inc, with corporate headquarters based in Frazer, PA.  Under his 22 years of leadership, Cephalon has grown to become the 8th largest biotech company in the world, with 8 proprietary products in the U.S. and dozens of products available in 100 countries.  The company went public in 1991 and listed on the NASDAQ stock exchange.  Just 10 years after launching its first product into the market, it reached $2 billion in sales in 2009, has nearly 4,000 employees around the world and is ranked as a member of the Fortune 1000.companies

He chairs the Executive Council of the Harvard Division of Sleep Medicine and is a member of the Board of Trustees at Temple University, the University of the Sciences in Philadelphia, and The Franklin (formerly known as The Franklin Institute).  In addition, Dr. Baldino serves as a member of the Board of Directors for the Greater Philadelphia Chamber of Commerce, the Eastern Technology Council, BioAdvance Biotechnology Greenhouse Corp., Quaker BioVentures, L.P., Valeritas, Inc., Viropharma Incorporated, and Pennsylvania BIO.  He is also a member of the Board of Directors for NicOx, S.A., and Acusphere, Inc.

Dr. Baldino received his Ph.D. in pharmacology from Temple University. From 1981-1987, he served as senior research biologist in the medical products department at E.I. duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents.   He has authored more than 100 publications in peer-reviewed journals such as Nature, Journal of Neuroscience Research, and Brain Research.